Effects of aromatase inhibitors on the ocular surface microenvironment

Effects of aromatase inhibitors on the ocular surface microenvironment

AIM: To analyze the effects of aromatase inhibitors(AIs)on the ocular surface microenvironment of the users.METHODS: A cross-sectional observational study was conducted. The study included postmenopausal women who received AIs treatment at galactophore department of our hospital from November 2022 t...

Full description

Bibliographic Details
Main Authors:	Peng Xu, Yuan-Yuan Zhao, Chen Yuan, Chao Liu
Format:	Article
Language:	English
Published:	Press of International Journal of Ophthalmology (IJO PRESS) 2023-10-01
Series:	Guoji Yanke Zazhi
Subjects:	dry eye aromatase inhibitor breast cancer ocular surface microenvironment
Online Access:	http://ies.ijo.cn/cn_publish/2023/10/202310026.pdf

Similar Items

Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
by: Tara Hyder, et al.
Published: (2021-07-01)

Aromatase inhibitors in the treatment of endometriosis
by: Radosław Słopień, et al.
Published: (2016-03-01)

Molecular Docking of Aromatase Inhibitors
by: Virapong Prachayasittikul, et al.
Published: (2011-04-01)

Evaluation of Arthralgia Induced by Aromatase Inhibitor Therapy
by: Gulabi Mese, et al.
Published: (2013-02-01)

From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors
by: Leonor Vasconcelos de Matos, et al.
Published: (2021-02-01)

Art of prevention: The importance of dermatologic care when using aromatase inhibitors
by: Sara Behbahani, MD, MS, et al.
Published: (2021-12-01)

AROMATASE INHIBITORS IN BREAST CANCER THERAPY
by: Hande Karahan, et al.
Published: (2011-04-01)

Aromatase-Inhibitor-Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model
by: Nicholas A. Young, et al.
Published: (2022-12-01)

Aromatase Inhibitors and Risk of Metabolic and Cardiovascular Adverse Effects in Breast Cancer Patients—A Systematic Review and Meta-Analysis
by: Kamila Boszkiewicz, et al.
Published: (2022-05-01)

A REGENERATIVE APPROACH TO AN ACUTE EXACERBATION OF HIP PAIN FROM AROMATASE INHIBITOR ASSOCIATED MUSCULOSKELETAL SYNDROME AND AROMATASE-INHIBITOR ARTHRALGIAS
by: Christian Vangeison, et al.
Published: (2022-10-01)

Risks of Aromatase Inhibitor-Related Cardiotoxicity in Patients with Breast Cancer in Asia
by: Wei-Ting Chang, et al.
Published: (2022-01-01)

Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan
by: Sung-Chao Chu, et al.
Published: (2020-01-01)

The Role of Aromatase Inhibitors in Male Prolactinoma
by: Amit Akirov, et al.
Published: (2023-02-01)

Reconsidering Aromatase for Breast Cancer Treatment: New Roles for an Old Target
by: Jessica Caciolla, et al.
Published: (2020-11-01)

What influences aromatase inhibitor continuation intention among breast cancer survivors?
by: Young Kyung Seo, et al.
Published: (2021-03-01)

Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
by: Wonjin Kim, et al.
Published: (2015-03-01)

Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study
by: Maria Sund, et al.
Published: (2021-10-01)

Computational drug designing of fungal pigments as potential aromatase inhibitors
by: Nighat Fatima, et al.
Published: (2014-11-01)

Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer
by: Xuan Ge, et al.
Published: (2022-09-01)

Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis
by: Yang He, et al.
Published: (2019-10-01)

Aromatase inhibitors: the journey from the state of the art to clinical open questions
by: Daniele Generali, et al.
Published: (2023-12-01)

Sweet’s Syndrome Induced by Aromatase Inhibitor in the Treatment of Early Breast Cancer
by: Debora Cardoso, et al.
Published: (2020-02-01)

Origin of aromatase inhibitory activity via proteochemometric modeling
by: Saw Simeon, et al.
Published: (2016-05-01)

Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions
by: Daniele Generali, et al.
Published: (2024-01-01)

Oxylipins as Biomarkers for Aromatase Inhibitor-Induced Arthralgia (AIA) in Breast Cancer Patients
by: Jessica A. Martinez, et al.
Published: (2023-03-01)

Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects
by: Sara Tenti, et al.
Published: (2020-08-01)

Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event
by: Nikolaos Mitsimponas, et al.
Published: (2018-08-01)

Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
by: Angeliki Andrikopoulou, et al.
Published: (2021-01-01)

Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer
by: Li Huifang, et al.
Published: (2022-12-01)

Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer
by: Stefano Gonnelli, et al.
Published: (2008-12-01)

Aromatase inhibitors in male sex
by: Santosh Kumar Singh
Published: (2013-01-01)

Ocular surface condition in patients with pseudoexfoliative syndrome
by: V. V. Potemkin, et al.
Published: (2016-03-01)

Cannabidiol as a Promising Adjuvant Therapy for Estrogen Receptor-Positive Breast Tumors: Unveiling Its Benefits with Aromatase Inhibitors
by: Cristina Ferreira Almeida, et al.
Published: (2023-04-01)

The Effect of Metalloestrogens on the Effectiveness of Aromatase Inhibitors in a Hormone-Dependent Breast Cancer Cell Model
by: Kamila Boszkiewicz, et al.
Published: (2023-01-01)

Ocular Surface Side Effects of Novel Anticancer Drugs
by: Livio Vitiello, et al.
Published: (2024-01-01)

Physical Therapies for Psychosomatic Symptoms and Quality of Life Induced by Aromatase Inhibitors in Breast Cancer Patients: A Systematic Review and Meta-Analysis
by: Xue-Ying Zhu, et al.
Published: (2021-11-01)

Iatrogenic Ocular Surface Diseases Occurring during and/or after Different Treatments for Ocular Tumours
by: Giuseppe Giannaccare, et al.
Published: (2021-04-01)

Binding mode of triazole derivatives as aromatase inhibitors based on docking, protein ligand interaction fingerprinting, and molecular dynamics simulation studies
by: Ayyub Mojaddami, et al.
Published: (2017-01-01)

Design, Synthesis and Biological Evaluation of Aromatase Inhibitors Based on Sulfonates and Sulfonamides of Resveratrol
by: Marialuigia Fantacuzzi, et al.
Published: (2021-09-01)

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
by: Changjun Wang, et al.
Published: (2020-07-01)